Providing definitive therapy for cardio-vascular disorders through regenerative medicine and tissue engineering

Cardio Inc., a campus-based biotechnology corporation, is focused on the discovery, development, and commercialization of novel therapeutics -regenerative medicine and tissue engineering- that provide definitive and curative therapy for cardio-vascular disorders.
Our multifaceted research efforts encompass cell therapies, gene therapies, tissue engineering, and various interventional devices for regenerative medicine.


Topics / News Release

We now announce that EXCOR Pediatric, the ventricular assist device for children, has been approved the manufacture and sales by MHLW (Ministry of Health Labour and Welfare) on 18th June, 2015.

Copyright (C) 2017, Cardio Inc. All rights reserved.